, and bones, and it�s not clear how the drugs will affect them after long-term use.
.
.
.
.
.
.
�we have waited a long time and we cannot possibly wait any longer,� karmenu vella, european commissioner for environment, told the guardian.
.
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people.
.
�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement.
.